丙氨瑞林联合莉芙敏片对子宫内膜异位症患者p53、p21、MDM2蛋白表达及疗效的影响观察  

Effect of Alarelin Combined with Remifemin Tablets on the Protein Expression of p53,p21 and MDM2 and Efficacy in Patients with Endometriosis

作　　者：赵小卫 周建平 

机构地区：[1]重庆市大足区人民医院妇产科,重庆402360

出　　处：《中国药师》2016年第11期2086-2087,2137,共3页China Pharmacist

摘　　要：目的:观察促性腺激素释放激素激动药丙氨瑞林联合莉芙敏片治疗子宫内膜异位症,对患者p53、p21、MDM2蛋白表达的影响。方法:子宫内膜异位症患者276例随机分为观察组(149例)和对照组(127例)。观察组患者予丙氨瑞林联合莉芙敏片治疗,对照组患者仅予丙氨瑞林治疗,两组疗程均为8个月。比较两组患者治疗前后p53、p21、MDM2蛋白表达阳性率,观察两组患者临床症状的改善以及药品不良反应。结果:治疗后,两组患者p53、MDM2、p21阳性率较治疗前均明显降低(P<0.05),且观察组患者p53、p21、MDM2蛋白表达阳性率明显低于对照组(P<0.05);对照组患者的症状无改善,并有所加重,差异无统计学意义(P>0.05),但观察组患者痛经、月经异常、性交疼痛等症状均较治疗前明显改善(P<0.05),且明显优于对照组(P<0.05)。观察组总不良反应发生率为35.57%,低于对照组的55.91%(P<0.05)。结论:丙氨瑞林联合莉芙敏片治疗子宫内膜异位症,能够有效地降低患者p52、p21、MDM2的阳性表达率,改善患者症状,减少药品不良反应。Objective： To explore the influence of gonadotropin-releasing hormone agonist alarelin combined with remifemin on the protein expression of p53, p21 and MDM2 in endometriosis patients. Methods： Totally 276 cases of ectopic endometrium patients were selected and divided into two groups, the observation group （ 149 cases） and the control group （ 127 cases）. The observation group was treated with alarolin combined with remifemin, while the control group was only treated with alarelin, and the course of treatment was four months. The protein expression of p53, p21 and MDM2 in both groups was compared before and after the treatment, and the efficacy and adverse reactions were observed after the treatment. Results： After the treatment, the positive rates of p53 ,MDM2 ,and p21 were significantly lower than those before the treatment（P 〈0.05）. After the treatment, the positive rates of p21, p53 and MDM2 in the observation group were significantly lower than those in the control group（ P 〈 0.05 ）. In the control group, the symptoms were not improved, even worse, while the difference was not statistically significant（ P 〉 0.05 ）. Dysmenorrhea, menstrual abnormalities, sexual intercourse pain and the other symptoms were significantly reduced in both groups （ P 〈 0.05 ）, and the effect of the observation group was significantly better than that of the control group with significant difference （ P 〈 0.05 ）. The total incidence of adverse reactions was 35.57% in the observation group, which was lower than that （55.91%） in the control group with statistically significant difference （P 〈 0.05 ）. Conclusion： Alarelin combined with remifemin can effectively reduce the positive expression rates of p21, MDM2 and p52, improve patients＇ symptoms and reduce adverse reactions in the patients with endometriosis.

关 键 词：丙氨瑞林 莉芙敏片 促性腺激素释放激素激动药 P53 P21 子宫内膜异位症 

分 类 号：R984[医药卫生—药品]